Biogen Inc

Biogen Inc discovers develops manufactures and delivers therapies for treating neurological and neurodegenerative diseases The company offers TECFIDERA VUMERITY AVONEX PLEGRIDY TYSABRI and FAMPYRA for multiple sclerosis MS SPINRAZA for spinal muscular atrophy and FUMADERM to treat plaque psoriasis It also provides BENEPALI an etanercept biosimilar referencing ENBREL ADUHELM for the treatment of Alzheimers disease IMRALDI an adalimumab biosimilar referencing HUMIRA and FLIXABI an infliximab biosimilar referencing REMICADE In addition the company offers RITUXAN for treating nonHodgkins lymphoma chronic lymphocytic leukemia CLL rheumatoid arthritis two forms of ANCAassociated vasculitis and pemphigus vulgaris RITUXAN HYCELA for nonHodgkins lymphoma and CLL GAZYVA to treat CLL and follicular lymphoma and OCREVUS for treating relapsing MS and primary progressive MS and other antiCD20 therapies Further it develops BIIB135 BIIB061 BIIB091 and BIIB107 for MS and neuroimmunology Aducanumab Lecanemab BIIB076 and BIIB080 to treat Alzheimers disease and dementia BIIB067 BIIB078 BIIB105 BIIB100 and BIIB110 to treat neuromuscular disorders BIIB124 BIIB094 BIIB118 BIIB101 and BIIB122 for treating Parkinsons disease and movement disorders BIIB125 and BIIB104 for treating neuropsychiatry Dapirolizumab pegol and BIIB059 to treat immunology related diseases BIIB093 and BIIB131 to treat acute neurology BIIB074 for neuropathic pain and BYOOVIZ BIIB800 and SB15 biosimilars which are under various stages of development The company has collaboration and license agreements with Acorda Therapeutics Inc Alkermes Pharma Ireland Limited Denali Therapeutics Inc Eisai Co Ltd Genentech Inc Neurimmune SubOne AG Ionis Pharmaceuticals Inc Samsung Bioepis Co Ltd Sangamo Therapeutics Inc and Sage Therapeutics Inc Biogen Inc was founded in 1978 and is headquartered in Cambridge Massachusetts